Q3 2023 DiaSorin SpA Earnings Call Transcript
Good afternoon. This is the Chorus Call conference operator. Welcome, and thank you for joining the DiaSorin 9 Months 2023 Results Conference Call. (Operator Instructions)
At this time, I would like to turn the conference over to Mr. Carlo Rosa, CEO of DiaSorin. Please go ahead, sir.
Thank you, operator, and good morning, good afternoon, and welcome to the Q3 conference call. As usual, I'm going to give some comments. At constant exchange rate, about the 3 legs of the business, the Immunodiagnostic, the Molecular Diagnostic and the Licensed Technology, and then I will let our CFO go through the numbers.
So if we start from the overall results, the quarter was in line with our expectation. Growth excluding COVID at constant exchange rate, it was 2% in the quarter, over 3% year-to-date. So it's in line with guidance and expectations, although if we look at the 3 legs of the business, we have different results.
So let's start from the Immunodiagnostics. Immunodiagnostics
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |